Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Merck
Baxter
Dow
Mallinckrodt

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

XHANCE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Xhance, and when can generic versions of Xhance launch?

Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are fifteen patents protecting this drug.

This drug has two hundred and forty-seven patent family members in twenty-eight countries.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Drug patent expirations by year for XHANCE
Drug Prices for XHANCE

See drug prices for XHANCE

Recent Litigation for XHANCE

Identify potential future generic entrants

District Court Litigation
Case NameDate
ADAMAS PHARMA, LLC v. SANDOZ INC.2018-05-10

See all XHANCE litigation

Pharmacology for XHANCE
Synonyms for XHANCE
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-14-yl propanoate
(6?,11?,16?,17?)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid fluoromethyl ester
(6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid S-(fluoromethyl) ester
[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
474F142
6alpha,9-difluoro-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-11beta-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate
80474-14-2
AB00513992
AB00513992_08
AB00513992-06
AB1010912
AC-457
AC1L9FLD
AJ-47435
AKOS015895220
AN-584/43505443
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester
Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, S-(fluoromethyl) ester, (6-alpha,11-beta,16-alpha,17-alpha)-
ArmonAir RespiClick
ArmonAir RespiClickTM
Asmatil
atemur
Axotide
BC216013
BDBM50354849
BIF0710
BPBio1_001203
BR-72799
BRD-K62310379-001-03-0
Brethal
BSPBio_001093
C25H31F3O5S
CCG-100981
CCI 18781
CCI-18781
CHEBI:31441
CHEMBL1473
CS-1986
Cultivate
Cutivate
Cutivate (TN)
D01708
DB00588
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
Flixotide Disks
Flixotide Inhaler
Flonase
Flonase (TN)
Flonase Allergy Relief
Flonase Aq
Flovent
Flovent (TN)
Flovent Diskus
Flovent Diskus 100
Flovent Diskus 250
Flovent Diskus 50
Flovent HFA
Flovent Rotadisk
Flovent-hfa
Fluinol
Flunase
Flusonal
Fluspiral
Fluticasone (propionate)
Fluticasone Impurity B
FLUTICASONE PROPIONATE
Fluticasone propionate (Flonase, Veramyst)
Fluticasone propionate (JAN/USAN)
Fluticasone propionate [USAN:USP]
Fluticasone propionate [USAN]
Fluticasone propionate for impurity C identification, EuropePharmacopoeia (EP) Reference Standard
Fluticasone propionate for impurity G identification, EuropePharmacopoeia (EP) Reference Standard
Fluticasone propionate, >=98% (HPLC), powder
Fluticasone propionate, European Pharmacopoeia (EP) Reference Standard
Fluticasone Propionate, Pharmaceutical Secondary Standard; Certified Reference Material
Fluticasone propionate, United States Pharmacopeia (USP) Reference Standard
Fluticasonpropionat Allen
Flutide
Flutivate
Fluxonal
FN-25
FT-0082893
GTPL7080
HMS1571G15
HMS2051N19
HMS2098G15
HMS3715G15
HY-B0154
Inalacor
KS-1173
LS-19323
MFCD00866007
MLS001424085
MolPort-003-847-468
NC00231
NCGC00179308-01
NCGC00179308-05
O2GMZ0LF5W
Prestwick0_000997
Prestwick1_000997
Prestwick2_000997
Prestwick3_000997
Q-101393
Rinosone
RS0009
S-(Fluoromethyl) 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate, 17-propionate
S-(fluoromethyl)-6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate,17-propionate
s1992
SC-19333
SCHEMBL4068
Skyron
SMR000469159
SPBio_002984
SR-01000763355
SR-01000763355-3
ST2407016
Trialona
Ubizol
UNII-O2GMZ0LF5W
WMWTYOKRWGGJOA-CENSZEJFSA-N
ZINC3920027
Zoflut

US Patents and Regulatory Information for XHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for XHANCE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 2018C/022 Belgium   Start Trial PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1305329 SPC/GB08/026 United Kingdom   Start Trial PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
1519731 92269 Luxembourg   Start Trial PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1519731 13C0067 France   Start Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1305329 08C0014 France   Start Trial PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844 1890025-8 Sweden   Start Trial PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
Dow
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.